Syndax Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of AUGMENT-101 Trial of Revumenib in Patients with Acute Leukemias

- 30% CR/CRh rate and 53% ORR in R/R acute leukemia patients with NPM1 or MLLr (KMT2Ar) mutations; no discontinuations due to treatment-related adverse events...

Related Keywords

United States ,American ,Ghayas Issa ,Sharon Klahre ,Michaela Metzger ,Company On Twitter ,Linkedin ,Syndax Pharmaceuticals ,European Commission ,Drug Administration ,Nasdaq ,Exchange Commission ,American Society Of Hematology ,International Number ,Prnewswire Syndax Pharmaceuticals Inc ,Syndax Pharmaceuticals Inc ,American Society ,Annual Meeting ,Chief Executive ,New Drug Application ,Response Rate ,Menin Inhibitor ,Durable Responses ,Updated Results ,Myeloid Leukemias ,Investigational Therapies ,Excluding Transplantation ,Patients Achieving Remissions ,Menin Inhibition ,Long Term Follow Up ,Disease Recurrence ,Dial In Number ,Mixed Lineage Leukemia ,Rearranged Acute ,Acute Myeloid ,Orphan Drug Designation ,Fast Track ,Private Securities Litigation Reform Act ,Nc ,